TP53 and esophageal squamous cell carcinoma: Previous studies indicated that mutations in the tumor suppressor TP53 are frequently detected in some of the ESCC and HNSCC patients at the initial stage [43, 44] and are correlated with poor survival and high metastatic rates [45, 46].